Medical Necessity, Referral Arrangements, Billing Practices, and Executive Liability Remain Central Enforcement Risks
Federal enforcement involving clinical laboratories remains active, with recent Department of Justice (DOJ) actions targeting a broad range of practices, from medically unnecessary testing and improper referral arrangements to retained overpayments and allegedly fabricated claims. Between July and October 2026, DOJ announced several significant laboratory enforcement actions involving tens of millions of dollars in alleged improper reimbursement and civil settlements. Although the cases involve different facts and legal theories, they collectively highlight an important development for clinical laboratories: federal scrutiny extends beyond whether a test was performed to how it was ordered, why it was performed, how it was billed, and who benefited financially. For independent laboratories, these cases offer important guidance on where compliance vulnerabilities may arise and how providers can distinguish legitimate reimbursement practices from arrangements that attract enforcement attention.
Recent Laboratory Enforcement Actions
October 2026: Laboratory Owner Charged in Alleged $66 Million COVID-19 Testing Scheme
On October 20, 2026, DOJ announced criminal charges against an Illinois laboratory owner accused of submitting approximately $66.2 million in fraudulent claims for COVID-19 testing. According to the indictment, the laboratory allegedly billed federal programs for hundreds of thousands of tests that were never performed. The charges remain allegations, and the defendant is presumed innocent unless proven guilty. The case demonstrates the continued federal pursuit of alleged pandemic-era billing misconduct, even years after the underlying services were purportedly furnished.
September 2026: Signal Diagnostics Agrees to $20.5 Million Settlement Over Retained Overpayments
On September 30, 2026, DOJ announced that Signal Diagnostics LLC agreed to pay $20.5 million to resolve allegations involving overpayments received through the HRSA COVID-19 Uninsured Program. The government alleged that the laboratory knowingly retained payments for testing patients who had health insurance and improperly avoided its repayment obligations. Unlike cases focusing primarily on false claims submitted at the outset, this matter concerned the alleged retention of funds after an obligation to repay arose. While an adverse billing finding does not necessarily establish an overpayment, credible information suggesting that a laboratory has received funds to which it is not entitled requires appropriate investigation and resolution.
September 2026: DOJ Pursues Individual Laboratory Executives Over Testing and Referral Practices
On September 17, 2026, DOJ filed a civil False Claims Act complaint against former executives of Capstone Diagnostics, alleging schemes involving genetic and respiratory pathogen testing. The government alleged that testing was generated through unlawful kickbacks and without individualized treating-provider judgment, including through health fairs, religious events, and senior living communities. According to DOJ, Medicare paid approximately $13.7 million for testing associated with the alleged schemes.
July 2026: Access DX Laboratory and Individuals Agree to $36.4 Million in Settlements
On July 30, 2026, DOJ announced combined settlements totaling $36.4 million involving Access DX Laboratory, its former CEO, and a businessman associated with alleged genetic testing schemes. The government's allegations included improper payments to marketers, medically unnecessary genetic testing, payments for fraudulent telemedicine orders, and unbundled billing. The settlement highlights the intersection of several enforcement theories: the Anti-Kickback Statute, False Claims Act, medical necessity requirements, and billing rules.
July 2026: LabCorp Agrees to Pay $14.5 Million Over Urine Drug Testing
On July 15, 2026, LabCorp agreed to pay $14.5 million to resolve allegations that it submitted claims to Medicare for medically unnecessary urine drug testing performed through its Toxassure Comprehensive testing panel. The case is particularly instructive because it concerns the use of a defined testing panel and emphasizes the importance of protocol evaluation, including physician ordering practices and claim submission procedures. Comprehensive panels are not inherently inappropriate. However, the medical necessity of ordered testing must be supportable under applicable coverage and reimbursement requirements.
What These Cases Tell Us About Federal Laboratory Enforcement
Several recurring themes emerge from these actions. First, medical necessity remains central. The performance of a laboratory test does not, by itself, establish entitlement to reimbursement. The test must satisfy applicable coverage requirements, including medical necessity and ordering requirements. Second, referral relationships remain a significant enforcement target. Marketing arrangements, payments to referral sources, telemedicine relationships, and other business development structures may create Anti-Kickback Statute exposure depending on their design and operation. Third, billing methodology matters and panel design, unbundling, coding, and claims submission practices can create separate reimbursement risks even where laboratory services were actually appropriately furnished.
Recent laboratory enforcement actions demonstrate that federal scrutiny is not confined to overtly fraudulent billing schemes. The government's cases increasingly illustrate how medical necessity, referral arrangements, billing practices, overpayment obligations, and executive decision-making can intersect. For legitimate laboratories, the objective should not be to avoid innovative testing models, commercial relationships, or appropriate reimbursement opportunities. It should be to ensure those arrangements are legally defensible, adequately documented, and consistent with applicable reimbursement requirements. A proactive review can help identify vulnerabilities before they result in payment suspensions, recoupment demands, government investigations, or False Claims Act litigation.
MDRXLAW represents independent clinical laboratories and other healthcare providers in government investigations, Medicare and Medicaid audits, reimbursement disputes, False Claims Act matters, and regulatory compliance. Our attorneys assist laboratories in evaluating medical necessity and billing concerns, reviewing marketing and referral arrangements, responding to payor and government inquiries, and developing legally sound strategies to address identified compliance risks. You may contact MDRXLAW to discuss a targeted laboratory regulatory and reimbursement risk assessment at info@mdrxlaw.com or 212.668.0200.
* This article is for informational purposes only and does not constitute legal advice. The settlements discussed resolve allegations without findings of liability unless otherwise stated. Criminal charges and civil complaints are allegations, and defendants are presumed innocent unless proven guilty *
